Researchers from Eberhard Karls University Tübingen and German Research Center for Environmental Health, Germany have found that sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, can reinstate insulin sensitivity in the brain, particularly the hypothalamus, and reduce fasting glucose levels and liver fat in prediabetes patients. The study has been published in the journal Diabetes Care. Here is an infographic on empagliflozin reinstating insulin sensitivity in the hypothalamus.
Take a look! Is nasal administration of SGLT2 inhibitors more beneficial than oral administration in treating diabetes?
